Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 44Carboplatin 40Cisplatin 36Paclitaxel 29Pemetrexed 24Nivolumab 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Fluorouracil 14Capecitabine 14atezolizumab 13Docetaxel 13trastuzumab deruxtecan 12Trastuzumab 12Lenalidomide 12durvalumab 11daratumumab 11Cytarabine 11olaparib 10Prednisone 10Bortezomib 10Bevacizumab 10130-nm albumin-bound paclitaxel 10Doxorubicin 9venetoclax 8Oxaliplatin 8Crizotinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has announcements × rucaparib × Clear all
NCT02975934 2025-07-25

TRITON3

pharmaand GmbH

Phase 3 Completed
405 enrolled 34 charts 1 FDA
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT01968213 2023-06-09

ARIEL3

pharmaand GmbH

Phase 3 Completed
564 enrolled 18 charts 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02952534 2023-06-09

TRITON2

pharmaand GmbH

Phase 2 Completed
277 enrolled 23 charts 1 FDA

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related

Data powered by HemOnc (CC BY 4.0) Colophon âš¡